DRC Approves Clinical Trials For Experimental Ebola Treatments; U.N. Notes Increase In Cases Among Newborns

Al Jazeera: DRC: Ebola clinical trials begin as U.N. warns of newborns infected
“Authorities in the Democratic Republic of the Congo (DRC) have approved clinical trials for four experimental Ebola treatments, even as the deadly disease’s outbreak among newborn babies raises new fears…” (11/24).

Associated Press: Congo starts first-ever trial testing Ebola drugs
“Congo has begun the first-ever trial to test the effectiveness and safety of four experimental Ebola drugs, the first time scientists have directly compared such treatments, the World Health Organization said Monday. The U.N. health agency described the multi-drug trial as ‘a giant step’ that would ‘bring clarity about what works best’…” (Petesch, 11/26).

Axios: Ebola outbreak in Congo getting close to becoming 2nd biggest ever
“The Ebola outbreak in the Democratic Republic of the Congo (DRC) continues to steadily grow — creeping closer to becoming the second largest outbreak recorded globally (current second highest is 425 cases). [Friday], the DRC reported 399 confirmed and probable cases for this outbreak that started Aug. 1…” (O’Reilly, 11/23).

Additional coverage of the Ebola outbreak and response in the DRC is available from Agence France-Presse, Associated Press, CIDRAP News, Deutsche Welle, Devex, and Reuters.

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.